中枢神经系统治疗市场：依疾病、药物类别划分 - 全球预测 2023-2030

全球中枢神经系统治疗市场预计将大幅成长，到2023年将达到701.7亿美元，年复合成长率为9.30%，到2030年将达到1313.9亿美元。

FPNV定位矩阵

FPNV定位矩阵对于评估全球中枢神经系统治疗市场至关重要。透过检查业务策略和产品满意度的关键指标，我们对供应商进行全面评估，使您能够根据您的特定需求做出明智的资讯。这种进阶分析将供应商分为四个像限，并取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市占率分析

市场占有率分析可以深入了解供应商在特定市场领域的当前地位。比较供应商对总收入、基本客群和其他关键指标的贡献，可以帮助公司更好地了解他们在争夺市场份额时的表现以及面临的情况。该分析还揭示了特定行业的竞争程度、累积和合併的优势以及研究基准年的合併特征。

本报告提供了以下几点见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开发：提供有关利润丰厚的新兴市场的详细资讯，并分析其在成熟市场的渗透率。

3. 市场多元化：提供有关新产品发布、未开发领域、最新发展和投资的详细资讯。

4.市场趋势：全面了解COVID-19、俄罗斯-乌克兰衝突和高通膨的累积影响。

5.竞争评估与资讯：对主要企业的市场占有率、策略、产品、认证、法规状况、专利状况、製造能力等进行综合评估。

6. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告回答了以下问题：

1.中枢神经系统治疗的全球市场规模与预测为何？

2.在预测期内，COVID-19对全球中枢神经系统治疗市场的阻碍因素与影响有哪些？

3.在预测期内，全球中枢神经系统治疗市场需要投资哪些产品/细分市场/应用/领域？

4.全球中枢神经系统药物市场的竞争策略为何？

5.全球中枢神经系统药物市场的技术趋势和法律规范是什么？

6.全球中枢神经系统治疗市场主要厂商的市占率为何？

7. 哪些型态和策略性措施被认为适合进入全球中枢神经系统药物市场？

目录

第1章前言

第2章调查方法

第3章执行摘要

第4章市场概况

第5章市场洞察

• 市场动态
  • 促进因素
    • 中枢神经系统疾病盛行率不断上升，对有效治疗方案的需求不断增加
    • 由于主要产品的专利专利到期，仿製药的批准增加
    • 改善新兴市场的医疗保健基础设施
  • 抑制因素
    • 对新疗法价格上涨的担忧
  • 机会
    • 中枢神经系统疾病的诊断和治疗进展
    • 製药公司持续研发努力
  • 任务
    • 严格且延长的药品审批程序
• 市场趋势
• COVID-19 的累积影响
• 俄罗斯-乌克兰衝突的累积影响
• 高通膨的累积效应
• 波特五力分析
• 价值炼和关键路径分析
• 法律规范
• 客户客製化

第6章依疾病区分的中枢神经系统治疗药物市场

• 癌症
• 退化性疾病
  • 阿兹海默氏症
  • 肌萎缩侧索硬化症
  • 多发性硬化症
  • 帕金森氏症
• 感染疾病
• 精神健康
  • 焦虑症
  • 癫痫
  • 精神障碍
• 神经血管疾病
• 创伤

第7章依药物类别分類的中枢神经系统治疗市场

• 止痛药
• 麻醉剂
• 抗癫痫药
• 抗帕金森氏症药物
• 抗忧郁药
• 中枢神经系统兴奋剂

第8章美洲中枢神经系统治疗市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第9章亚太中枢神经系统治疗市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第10章欧洲、中东和非洲中枢神经系统治疗药物市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第11章竞争形势

• FPNV定位矩阵
• 市占率分析：主要企业
• 竞争情境分析：主要企业

第12章上市公司名单

第13章附录

• 讨论指南
• 关于许可证和定价

The Global Central Nervous System Therapeutics Market is forecasted to grow significantly, with a projected USD 70.17 billion in 2023 at a CAGR of 9.30% and expected to reach a staggering USD 131.39 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Central Nervous System Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Central Nervous System Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Diseases, market is studied across Cancer, Degenerative Diseases, Infectious Diseases, Mental Health, Neurovascular Diseases, and Trauma. The Degenerative Diseases is further studied across Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, and Parkinson's Disease. The Mental Health is further studied across Anxiety Disorders, Epilepsy, and Psychotic Disorders. The Infectious Diseases is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Analgesics, Anesthetics, Anti-Epileptics, Anti-Parkinson Drugs, Antidepressant, and CNS stimulants. The Antidepressant is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Central Nervous System Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Central Nervous System Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Central Nervous System Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Central Nervous System Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Central Nervous System Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Central Nervous System Therapeutics Market?

6. What is the market share of the leading vendors in the Global Central Nervous System Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Central Nervous System Therapeutics Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Central Nervous System Therapeutics Market, by Diseases, 2022 vs 2030
• 4.3. Central Nervous System Therapeutics Market, by Drug Class, 2022 vs 2030
• 4.4. Central Nervous System Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of CNS disorders and increasing demand for effective therapeutic options
    • 5.1.1.2. Increasing approval of generic products due to patent expiration of key products
    • 5.1.1.3. Improving healthcare infrastructure in emerging markets
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with increasing prices of new treatments
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in diagnostics and therapeutics of CNS diseases
    • 5.1.3.2. Constant R&D efforts by pharmaceutical companies
  • 5.1.4. Challenges
    • 5.1.4.1. Strict & extended drug approval procedures
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Central Nervous System Therapeutics Market, by Diseases

• 6.1. Introduction
• 6.2. Cancer
• 6.3. Degenerative Diseases
  • 6.3.1. Alzheimer's Disease
  • 6.3.2. Amyotrophic Lateral Sclerosis
  • 6.3.3. Multiple Sclerosis
  • 6.3.4. Parkinson's Disease
• 6.4. Infectious Diseases
• 6.5. Mental Health
  • 6.5.1. Anxiety Disorders
  • 6.5.2. Epilepsy
  • 6.5.3. Psychotic Disorders
• 6.6. Neurovascular Diseases
• 6.7. Trauma

7. Central Nervous System Therapeutics Market, by Drug Class

• 7.1. Introduction
• 7.2. Analgesics
• 7.3. Anesthetics
• 7.4. Anti-Epileptics
• 7.5. Anti-Parkinson Drugs
• 7.6. Antidepressant
• 7.7. CNS stimulants

8. Americas Central Nervous System Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Central Nervous System Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Central Nervous System Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing

LIST OF FIGURES

• FIGURE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2022 VS 2030
• FIGURE 3. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2022 VS 2030 (%)
• FIGURE 5. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
• FIGURE 6. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET DYNAMICS
• FIGURE 8. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 5. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 7. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 14. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANXIETY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY NEUROVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY TRAUMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 21. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANESTHETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTI-PARKINSON DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY CNS STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 41. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 42. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 43. CANADA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 56. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 60. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 61. AUSTRALIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 63. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 64. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 65. CHINA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 67. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 68. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 69. INDIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 72. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 73. INDONESIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 76. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 77. JAPAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 80. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 81. MALAYSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 84. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 85. PHILIPPINES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 88. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 89. SINGAPORE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 92. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 93. SOUTH KOREA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 96. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 97. TAIWAN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 100. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 101. THAILAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 104. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 105. VIETNAM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 109. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 110. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 113. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 114. DENMARK CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 117. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 118. EGYPT CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 121. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 122. FINLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 125. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 126. FRANCE CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 129. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 130. GERMANY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 133. ISRAEL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 134. ISRAEL CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 136. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 137. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 138. ITALY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 141. NETHERLANDS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 142. NETHERLANDS CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 145. NIGERIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 146. NIGERIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 149. NORWAY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 150. NORWAY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 151. POLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 152. POLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 153. POLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 154. POLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 155. QATAR CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 156. QATAR CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 157. QATAR CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 158. QATAR CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 161. RUSSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 162. RUSSIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 165. SAUDI ARABIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 166. SAUDI ARABIA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH AFRICA CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 173. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 174. SPAIN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 177. SWEDEN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 178. SWEDEN CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 181. SWITZERLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 182. SWITZERLAND CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 185. TURKEY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 186. TURKEY CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 189. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 190. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DISEASES, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DEGENERATIVE DISEASES, 2018-2030 (USD MILLION)
• TABLE 193. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH, 2018-2030 (USD MILLION)
• TABLE 194. UNITED KINGDOM CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 195. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 196. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 197. CENTRAL NERVOUS SYSTEM THERAPEUTICS MARKET LICENSE & PRICING